- Home
- BCSF vs AURA Comparison
BCSF vs AURA Comparison
Compare BCSF & AURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BCSF | AURA |
|---|---|---|
| Founded | 2015 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 870.5M | 713.4M |
| IPO Year | 2015 | 2021 |
Fundamental Metrics
Financial Performance| Metric | BCSF | AURA |
|---|---|---|
| Price | $12.79 | $6.63 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $14.00 | ★ $20.00 |
| AVG Volume (30 Days) | 321.1K | ★ 442.7K |
| Earning Date | 05-11-2026 | 05-08-2026 |
| Dividend Yield | ★ 14.61% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.05 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $264.60 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.82 | $4.73 |
| 52 Week High | $16.00 | $9.54 |
Technical Indicators
Market Signals| Indicator | BCSF | AURA |
|---|---|---|
| Relative Strength Index (RSI) | 40.19 | 32.78 |
| Support Level | $12.49 | $5.33 |
| Resistance Level | $13.74 | $7.04 |
| Average True Range (ATR) | 0.33 | 0.35 |
| MACD | -0.06 | -0.15 |
| Stochastic Oscillator | 7.79 | 4.56 |
Price Performance
Historical ComparisonAbout BCSF Bain Capital Specialty Finance Inc.
Bain Capital Specialty Finance Inc is an externally managed, closed-end, non-diversified management investment company. The company's objective is to provide risk-adjusted returns and current income to investors by investing in middle-market companies. Its portfolio of investments includes First Lien Senior Secured Loan, Preferred Equity, Equity Interest, Warrants, and Second Lien Senior Secured Loan, and others.
About AURA Aura Biosciences Inc.
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.